New Research Initiatives from ESSO: Go Safe & Corsica 20/04/2017
Go Safe: Evaluating Functional Outcomes after Cancer Surgery in Geriatric Patients
Promoted by ESSO and the surgical task force of SIOG (International Society of Geriatric Oncology), GO SAFE (Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery) is a new research study that will evaluate postoperative functional outcomes and quality of life after cancer surgery in geriatric patients.
Given the global progressive aging, national healthcare systems must cope with an increasingly old population of cancer patients. The presence of comorbidities and frailties in the “over 70” age-group is often responsible for poor postoperative outcomes. Moreover, despite the progress achieved in surgical oncology, senior adults affected by cancer are often treated sub-optimally. Apart from survival, quality of life and functional recovery after surgery are rarely reported, and there is a general lack of knowledge about postoperative outcomes in older cancer patients.
Recently launched under the lead of the Chief Investigator Prof. Giampaolo Ugolini (Bologna, Italy) as well as several ESSO experts – including the immediate Past President Prof. Riccardo Audisio (Liverpool, UK) – GO SAFE is an international high-quality registry which addresses this problem and prospectively investigates how frailty, comorbidities and malnourishment are associated with clinical outcomes after surgery for solid malignancies in this patient population.
The study enrolled its first patient in February 2017, and it involves units from various countries that perform cancer surgery in elderly cancer patients. Go Safe focuses on patients’ quality of life and functional recovery, comparing the pre- and postoperative situation through a self-reported assessment tool. The findings of GO SAFE will assist clinicians in assessing patients as well as in tailoring their care, avoiding under/overtreatment and identifying new strategies to improve functional outcomes. Its final objective is to ensure as much as possible a satisfactory quality of life after treatment as well as the conservation of independence to onco-geriatric patients.
Should you be interested in joining this research collaboration and/or in receiving more information about GO SAFE, please don't hesitate to contact the research coordinator at: email@example.com
CORSiCA: Investigating Rectal Cancers’ Nodal Positivity Before Surgery
Conceived in the framework of the EYSAC young researchers' activities, CORSiCA ‘Complete pathologic response rectal cancers EYSAC.1 Study’ will investigate complete responders’ rectal cancers at the European level.
About 20% of patients with rectal cancers who received neoadjuvant treatment achieve a pathological complete response in the surgical specimen (ypT0). However, about 10% of ypT0 present metastatic nodes and, thus, the identification of surgical specimen with metastatic nodes could be crucial to tailor future treatments and improve their chances of cure. The purpose of the CORSiCA project is to build a large database with the clinical, pathological and radiological data of pathologic complete responders, to study ypT0 rectal cancers in relation to the nodal status and, thus, predict the nodal positivity before surgical treatment.
After having conducted at the Italian level a retrospective multi-centric study on 230 ypT0 focused on treatment and outcomes, the Research Delegate of the ESSO Young Surgeons and Alumni Club (EYSAC) Steering Committee Dr. Laura Lorenzon (Sapienza University of Rome, Italy) has been appointed as the Principal Investigator of this new project. After having received an encouraging evaluation from the European Research Council, the project will soon start and receive funds from different sources, including the University La Sapienza of Rome, Italy.
ESSO will be a project partner in CORSiCA, thanks to the precious project contribution of Prof. Geerard Beets from the ESSO Education Committee (Netherlands Cancer Institute, Amsterdam), President of the Italian Society of Surgical Oncology Prof. Paolo Delrio (National Cancer Institute “Pascale Foundation”, Naples) and EYSAC Chair Dr. Karol Polom (Poland/Italy).